A Single-centre, Randomised, Positive-controlled, Single-dose, Dose-escalation Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of peginterferon Alfa-2a in Healthy Subjects.

Trial Profile

A Single-centre, Randomised, Positive-controlled, Single-dose, Dose-escalation Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of peginterferon Alfa-2a in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2015

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B; Hepatitis C
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 30 Jan 2012 Actual initiation date changed from Dec 2010 to Jan 2011 as reported by ClinicalTrials.gov.
    • 30 Jan 2012 Actual patient number (39) added as reported by ClinicalTrials.gov.
    • 30 Jan 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top